Zenotech Laboratories

Zenotech Laboratories Receivables

The Accounts Receivable of Zenotech Laboratories (532039.BO) as of Oct 16, 2026 is 78.19 M INR. In the previous year, Accounts Receivable was 37.02 M INR — a change of 111.23% (higher).

Receivables

78.19 MINR

YoY

111.23%

Last updated:

Accounts Receivable of Zenotech Laboratories is 2025 78.19 M INR. Accounts Receivable of Zenotech Laboratories was 2024 37.02 M INR. It decreases by 111.23% higher compared to the previous year.

The Zenotech Laboratories Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
39,000.00 INR
Jan 1, 2019
24.80 M INR
Jan 1, 2020
18.57 M INR
Jan 1, 2021
38.03 M INR
Jan 1, 2022
39.28 M INR
Jan 1, 2023
33.24 M INR
Jan 1, 2024
37.02 M INR
Jan 1, 2025
78.19 M INR
The Zenotech Laboratories Receivables history
YEARReceivablesYoY
78.19 MINR+111.23%
37.02 MINR+11.38%
33.24 MINR-15.39%
39.28 MINR+3.29%
38.03 MINR+104.79%
18.57 MINR-25.12%
24.80 MINR+63,492.31%
39,000.00INR+254.55%
11,000.00INR-99.68%
3.47 MINR+285.89%
900,000.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 532039.BO and ISIN INE486F01012, is a biotechnology company operating in the healthcare sector. Headquartered in Hyderabad, India, the company employs 150 full-time staff. Founded through an IPO on May 14, 1996, Zenotech focuses on the manufacturing and marketing of pharmaceutical products, specifically specializing in specialty generic injectables. Its production facilities are located in Turkapally village, Shamirpet Mandal, Telangana. The company's product portfolio includes oncology, biotechnology, and general injectables. Zenotech Laboratories Ltd maintains a website at http://zenotechlab.com/ for further information. The firm's operations are centered around the development and distribution of injectable pharmaceutical solutions, targeting both domestic and international markets. With its focus on injectables, the company aims to provide accessible and reliable healthcare products. The company's headquarters in Hyderabad serves as the central hub for its business activities, including research, development, and administrative functions. Zenotech's business model emphasizes the production of generic injectables, which are critical for various medical treatments, particularly in oncology and biotechnology sectors. The company's presence in the Telangana region, with its manufacturing facility in Turkapally, underscores its commitment to local manufacturing and supply chain efficiency. As a publicly traded entity, Zenotech Laboratories Ltd. provides investors with exposure to the biotechnology and pharmaceutical sectors within India's healthcare industry. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Accounts Receivable of Zenotech Laboratories is 78.19 M INR in 2025.

Accounts Receivable of Zenotech Laboratories changed from 37.02 M INR to 78.19 M INR, representing a 111.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Zenotech Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories